Skip to content
lifestyle.social-matic.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
IGC Pharma, Inc.
IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis
June 2, 2026
IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment
May 23, 2026
IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference
May 23, 2026
IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase
April 29, 2026
IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion
April 28, 2026
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts
April 8, 2026
IGC Pharma Announces Equity Research Update by Alliance Global Partners
February 16, 2026
←
Previous Page
1
2